AURKA, aurora kinase A, 6790

N. diseases: 245; N. variants: 15
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0856825
Disease: Acute GVH disease
Acute GVH disease 		0.010 Biomarker disease BEFREE These data provide a comprehensive elucidation of the T cell transcriptome in primate acute GVHD and suggest that AURKA should be considered a target for preventing GVHD, which, given the many available AURKA inhibitors in clinical development, could be quickly deployed for the prevention of GVHD. 26606970 2015
CUI: C0023449
Disease: Acute lymphocytic leukemia
Acute lymphocytic leukemia 		0.010 GeneticVariation disease BEFREE CDKN1A-mediated responsiveness of MLL-AF4-positive acute lymphoblastic leukemia to Aurora kinase-A inhibitors. 24382688 2014
CUI: C0023462
Disease: Acute Megakaryocytic Leukemias
Acute Megakaryocytic Leukemias 		0.020 AlteredExpression disease BEFREE We further find that MLN8237 (Alisertib), a selective inhibitor of AURKA, induced polyploidization and expression of mature megakaryocyte markers in acute megakaryocytic leukemia (AMKL) blasts and displayed potent anti-AMKL activity in vivo. 22863010 2012
CUI: C0023462
Disease: Acute Megakaryocytic Leukemias
Acute Megakaryocytic Leukemias 		0.020 Biomarker disease BEFREE Clinical studies with polyploidy inducers, such as aurora kinase A inhibitors, are under way for a wide variety of malignancies, whereas trials specifically for AMKL and PMF are in development. 23963861 2013
CUI: C0457334
Disease: Acute monoblastic leukemia
Acute monoblastic leukemia 		0.010 AlteredExpression disease BEFREE Segmental amplification of MLL gene associated with high expression of AURKA and AURKB genes in a case of acute monoblastic leukemia with complex karyotype. 20303016 2010
CUI: C0023465
Disease: Acute monocytic leukemia
Acute monocytic leukemia 		0.020 Biomarker disease BEFREE Rescue experiment showed that AURKA attenuated the influence of lncRNA TUG1 on AML cell proliferation and apoptosis. 29654398 2018
CUI: C0023465
Disease: Acute monocytic leukemia
Acute monocytic leukemia 		0.020 AlteredExpression disease BEFREE Segmental amplification of MLL gene associated with high expression of AURKA and AURKB genes in a case of acute monoblastic leukemia with complex karyotype. 20303016 2010
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma 		0.070 AlteredExpression group BEFREE Using quantitative real-time PCR, we detected frequent AURKA gene amplification (15 of 34, 44%) and mRNA overexpression (37 of 44, 84%) in esophageal adenocarcinomas (P < 0.01). 22302096 2012
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma 		0.070 AlteredExpression group LHGDN Aurora kinase expression in colorectal adenocarcinoma: correlations with clinicopathological features, p16 expression, and telomerase activity. 18284933 2008
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma 		0.070 Biomarker group BEFREE Moreover, AURKA was principally up-modulated in moderately and poorly differentiated lung cancers (p<0.01), as well as in squamous and adenocarcinomas compared to the non-invasive bronchioloalveolar histotype (p=0.029). 21718475 2011
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma 		0.070 AlteredExpression group BEFREE In the present study, we report that prolonged overexpression of AURKA transgene in mammary epithelium driven by ovine β-lactoglobulin promoter, activated through multiple pregnancy and lactation cycles, results in the development of mammary adenocarcinomas with alterations in cancer-relevant genes and epithelial-to-mesenchymal transition. 27624071 2016
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma 		0.070 AlteredExpression group BEFREE The expression patterns of STK15 were examined by immunohistochemistry in 80 lung squamous cell carcinomas and adenocarcinomas and 20 normal lung tissues. 16792546 2006
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma 		0.070 GeneticVariation group BEFREE The immunohistochemical analysis of 130 tumors demonstrated moderate-to-strong immunostaining of AURKA in >50% of upper gastrointestinal adenocarcinomas. 18311783 2008
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma 		0.070 Biomarker group BEFREE In tumors with mixed features, there was also 100% concordance of ERG rearrangement and 94% concordance of AURKA and MYCN co-amplification between areas of NEPC and adenocarcinoma. 23358695 2013
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma 		0.070 AlteredExpression group LHGDN The immunohistochemical analysis of 130 tumors demonstrated moderate-to-strong immunostaining of AURKA in >50% of upper gastrointestinal adenocarcinomas. 18311783 2008
CUI: C0279628
Disease: Adenocarcinoma Of Esophagus
Adenocarcinoma Of Esophagus 		0.010 AlteredExpression disease BEFREE Immunohistochemical analysis showed overexpression of AURKA in more than two-thirds of esophageal adenocarcinoma tissue samples (92 of 132, 70%; P < 0.001). 22302096 2012
CUI: C1319315
Disease: Adenocarcinoma of large intestine
Adenocarcinoma of large intestine 		0.300 GeneticVariation disease UNIPROT
CUI: C0152013
Disease: Adenocarcinoma of lung (disorder)
Adenocarcinoma of lung (disorder) 		0.050 AlteredExpression disease BEFREE Clinically, AURKA displays high levels in NSCLC patients, and correlates with poor outcome of patients with lung adenocarcinoma. 28967900 2018
CUI: C0152013
Disease: Adenocarcinoma of lung (disorder)
Adenocarcinoma of lung (disorder) 		0.050 Biomarker disease BEFREE Therefore, AURKA plays important roles in the proliferation of human lung adenocarcinoma cells, which suggests that AURKA could be a promising tool for lung adenocarcinoma therapy. 27571708 2016
CUI: C0152013
Disease: Adenocarcinoma of lung (disorder)
Adenocarcinoma of lung (disorder) 		0.050 AlteredExpression disease BEFREE Treatment-induced activation of AURKA is associated with resistance to EGFR inhibitors in vitro, in vivo and in most individuals with EGFR-mutant lung adenocarcinoma. 30478424 2019
CUI: C0152013
Disease: Adenocarcinoma of lung (disorder)
Adenocarcinoma of lung (disorder) 		0.050 AlteredExpression disease BEFREE In the cancer genome atlas (TCGA) lung adenocarcinoma cohort, high expression levels of AURKA and TPX2 were associated with specifically improved overall survival upon taxane-based radiochemotherapy, but not in case of non-taxane-based radiochemotherapy, chemo- or radiotherapy only. 28869599 2018
CUI: C0152013
Disease: Adenocarcinoma of lung (disorder)
Adenocarcinoma of lung (disorder) 		0.050 Biomarker disease BEFREE <b>Conclusion:</b> The mRNA signature of AURKA, CDC20 and TPX2 were potential biomarkers for predicting poor prognosis of smoking related lung adenocarcinoma. 30588191 2018
CUI: C0854985
Disease: Adenocarcinoma of lung, stage I
Adenocarcinoma of lung, stage I 		0.010 AlteredExpression disease BEFREE Immunohistochemical staining of stage I lung adenocarcinoma tissues demonstrated a positive correlation between AURKA expression and phosphorylation of EGFR at Thr654 and Ser1046 in EGFR-mutant specimens, but not in EGFR-WT specimens. 23520446 2013
CUI: C0007112
Disease: Adenocarcinoma of prostate
Adenocarcinoma of prostate 		0.300 GenomicAlterations disease CGI
CUI: C0001430
Disease: Adenoma
Adenoma 		0.010 AlteredExpression group BEFREE For AURKA and PDGFRB, increased mRNA expression levels were verified at the protein level by immunohistochemical analysis of a series of adenomas and CRCs. 20358421 2010